basal cell carcinoma

Update on advanced basal cell carcinoma diagnosis and treatmentDespite increased insight on skin cancer risk factors, the incidence continues to rise worldwide. This review article summarizes new treatment options available, which help to redefine and expand the diagnosis of advanced BCC and allow dermatologists to offer more effective therapy to a broader population.
Staying current with therapeutic advances and expert insightsThis month we offer new insights and data to aid diagnosis and treatment of difficult conditions, as well as practical approaches to optimize outcomes.
Vismodegib study confirms safety, efficacy for BCCThe largest-ever vismodegib study in advanced basal cell carcinoma, the STEVIE study, confirms pivotal study findings in a real-world setting, helping dermatologists to provide a complete palette of skin cancer treatments.
Improving accuracy in NMSC diagnosisThe trend toward smaller biopsies may compromise the accuracy of dermatopathologists' diagnoses.
GlobalMed Technologies acquires Omnilux MedicalGlobalMed has represented medical and aesthetic dermatology brands, including BMT, CoolTouch and Radiancy, since 1996. Omnilux noninvasively treats dermatologic conditions, including acne, fine lines and wrinkles and non-melanoma skin cancer.
Cutting edge techniques provide options for skin cancerNew technologies for managing skin cancer were a topic of discussion at a scientific session at the American Society for Dermatologic Surgery’s 2015 annual meeting in Chicago in October. Seaver L. Soon, M.D., division of dermatology and dermatologic surgery at Scripps Clinic, La Jolla, Calif., was one of the moderators for the scientific discussion titled, “The Cutting Edge: New Technologies for Managing Skin Cancer.” Learn more
High-risk skin cancer needs multidisciplinary management
High-risk skin cancer needs multidisciplinary managementImmunosuppressed patients have a greater risk for developing high-risk non-melanoma skin cancer, which can typically be more aggressive in this patient population. As such, a multidisciplinary approach is required when contemplating appropriate treatment and management of this patient population.
Sonidegib offers new option for basal cell cancerA newly approved medication called sonidegib (Odomzo) gives physicians a second option in a class of medications designed to treat a small number of patients who suffer from locally advanced basal cell carcinoma and meet other criteria. Learn more
The neatest scientific advance in skin cancer treatmentIn the treatment of non-melanoma skin cancer, “the fastest-moving area—and the neatest from a science standpoint—is the class of drugs called hedgehog pathway inhibitors.”
Compliance critical with at-home txDue to the complexities and follow-up requirements of nonsurgical treatments for skin cancer, patient selection is critical. Expert offers tips for using various noninvasive treatment options for BCC, SCC, and melanoma.